Navigation Links
Telik Announces Patents on Compounds Related to TELINTRA
Date:6/10/2008

PALO ALTO, Calif., June 10 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK), announced today that the European Patent Office has issued notices of allowance for two applications covering new compounds related to one of Telik's lead clinical candidates, TELINTRA(R). Corresponding applications have already issued as patents in the United States; and other applications are pending in major countries worldwide.

TELINTRA is currently in Phase 2 clinical trials for the treatment of Myelodysplastic Syndrome, a form of pre-leukemia, and for Chemotherapy Induced Neutropenia, a common side effect of chemotherapy. Telik expects these applications and patents to provide broad intellectual property protection to compounds related to TELINTRA, according to Derek Freyberg, Ph.D., Telik's VP, Intellectual Property. The patents will help to broaden and strengthen Telik's intellectual property estate and may support additional clinical development candidates.

About Telik

Telik, Inc. of Palo Alto, California, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates.

This press release contains "forward-looking" statements, including statements regarding the impact and coverage of patents on Telik's intellectual property. These forward-looking statements are based upon Telik's current expectations. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements, including, among others, if clinical trials of TELINTRA are delayed or unsuccessful, Telik's business would suffer, if Telik's competitors develop and market products that are more effective than its product candidates, or obtain marketing approval before Telik does, Telik's commercial opportunity will be reduced or eliminated, and if Telik does not obtain regulatory approval to market products in the U.S. and foreign countries, Telik will not be permitted to commercialize these product candidates. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ended March 31, 2008. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELINTRA, TELCYTA, and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Telik Announces Preclinical Presentations at AACR Annual Meeting
2. Telik Reports Positive Results From Phase 1 Dose-Escalation Study of TELINTRA Tablets in Myelodysplastic Syndrome
3. Selective Insurance Group Announces Officer Appointments
4. Nonin(R) Medical Announces Strategic Relationship With Microsoft and its Microsoft HealthVault Platform
5. Shared Health(R) Announces New Data Exchange Platform
6. China Sky One Medical, Inc. Announces Guidance for Second Quarter and Full Year 2008
7. Insulet Corporation Announces Private Offering of $65 Million of Convertible Senior Notes
8. NBTY Announces Agreement to Purchase Leiner Health Products
9. CorVel Announces Record Earnings
10. SUA Insurance Company Announces Partnership With American Safety Indemnity Company
11. WellPoint Announces Appearance at Upcoming Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
(Date:6/23/2016)... -- Revolutionary technology includes multi-speaker listening to ... leaders in advanced audiology and hearing aid technology, has ... the world,s first internet connected hearing aid that opens ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... firsts,: , TwinLink™ - the first dual ...
Breaking Medicine Technology: